CO-STAR

Welcome to the CO-STAR study!

A multicenter, randomized, open-label, blinded-assessor, follow-up, phase 4 study in patients with rheumatoid arthritis who have completed the initial treatment part (active conventional therapy versus three biologic treatments) in the NORD-STAR study and have reached stable low disease activity (the CO-STAR study).

-25 patients included

Patients who do not qualify for dose de-escalation in the NORD-STAR study due to lack of remission, but have stable a low disease activity (2.8 < CDAI ≤ 10.0) will be asked to participate. The duration of the study will be 80 weeks. Subjects entering the study will be randomized to either treatment part A (early de-escalation) or treatment part B (late de-escalation).